Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Castle Biosciences Inc
(NQ:
CSTL
)
29.57
+2.04 (+7.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
721,727
Open
28.10
Bid (Size)
29.12 (1)
Ask (Size)
30.59 (1)
Prev. Close
27.53
Today's Range
28.10 - 30.45
52wk Range
12.07 - 30.45
Shares Outstanding
25,167,365
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
August 06, 2024
Via
Benzinga
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+34.65%
+34.65%
1 Month
+48.97%
+48.97%
3 Month
+21.34%
+21.34%
6 Month
+23.91%
+23.91%
1 Year
+58.04%
+58.04%
More News
Read More
Castle Biosciences Reports Second Quarter 2024 Results
August 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
July 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
July 29, 2024
Via
Benzinga
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
July 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
July 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Honored with Top Workplaces Awards
July 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Explode In July
July 08, 2024
Via
Benzinga
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 05, 2024
Via
Benzinga
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
June 24, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 19, 2024
Via
Benzinga
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
June 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
May 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
May 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
May 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
May 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
May 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
May 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
May 03, 2024
From
Castle Biosciences Inc.
Via
Business Wire
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Castle Biosciences Reports First Quarter 2024 Results
May 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
April 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
April 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.